Skip to content
2000
Volume 18, Issue 5
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has received increased attention. Great efforts are being undertaken to improve the noninvasive diagnosis of NAFLD, with the ultimate goal of optimizing treatment options and clinical outcomes. Research suggests that blood-borne biochemical markers can be used to distinguish simple steatosis from nonalcoholic steatohepatitis (NASH), thus reducing the need of liver biopsy. Future developments in the field of diagnostic biochemistry within the spectrum of NAFLD can make this approach ideal for screening and monitoring purposes. In this review, we provide an overview of the different blood-borne markers which have been recently proposed for differentiating simple steatosis from NASH. We will also consider the practical and statistical issues that seem to be limiting the effective integration of biomarkers into clinical development.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986711794480122
2011-02-01
2025-05-04
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986711794480122
Loading

  • Article Type:
    Research Article
Keyword(s): biomarkers; Nonalcoholic fatty liver disease; steatohepatitis; steatosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test